All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2021-01-27T17:34:10.000Z

Venetoclax combinations in mutant AML subtypes podcast: FLT3

Featured
Jan 27, 2021
Share:

Bookmark this article

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Naval Daver, MD Anderson Cancer Center, Houston, US, about venetoclax combinations in patients with FLT3-mutated AML.

Venetoclax combinations in mutant AML subtypes podcast: FLT3

Emerging data on venetoclax combinations in patients with FLT3-mutated AML have been presented at ASH 2020. FLT3 mutations are the most common mutations in patients with AML.

In this podcast, Daver discusses the results of a study comparing the combination of azacitidine plus venetoclax versus azacitidine plus placebo in patients with FLT3-mutated AML. He also talks about a study evaluating the combination of gilteritinib with venetoclax in patients with relapsed/refractory FLT3-mutated AML and reports the results of the first combination of decitabine + venetoclax + FLT3 inhibitor of clinician’s choice in patients with FLT3-mutated AML.

 

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 6 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox